{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:32:55Z","timestamp":1793338375080,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T00:00:00Z","timestamp":1403654400000},"content-version":"vor","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.jacc.2013.02.058","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T01:14:11Z","timestamp":1365038051000},"page":"2495-2502","source":"Crossref","is-referenced-by-count":328,"title":["The P-Glycoprotein Transport System and Cardiovascular Drugs"],"prefix":"10.1016","volume":"61","author":[{"given":"Jeffrey D.","family":"Wessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura T.","family":"Grip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.02.058_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2013.02.058_bib2","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jacc.2013.02.058_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1081\/DMR-120026871","article-title":"Clinical relevance of P-glycoprotein in drug therapy","volume":"35","author":"Lin","year":"2003","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.jacc.2013.02.058_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2009.03.017","article-title":"Drug interactions at the blood-brain barrier: fact or fantasy?","volume":"123","author":"Eyal","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In\u00a0vitro P-glycoprotein assays to predict the in\u00a0vivo interactions of P-glycoprotein with drugs in the central nervous system","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacc.2013.02.058_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/pr.58.2.7","article-title":"The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart","volume":"58","author":"Couture","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jacc.2013.02.058_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4682-6-2","article-title":"Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination","volume":"6","author":"Fenneteau","year":"2009","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.jacc.2013.02.058_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1067\/mjd.2002.126823","article-title":"Drug interactions: proteins, pumps, and P-450s","volume":"47","author":"Shapiro","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jacc.2013.02.058_bib9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.CIR.99.4.472","article-title":"P-glycoprotein in clinical cardiology","volume":"99","author":"Rodriguez","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.02.058_bib10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026043387692","article-title":"Pharmacogenetics of drug transporters and its impact on the pharmacotherapy","volume":"4","author":"Sakaeda","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jacc.2013.02.058_bib11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0006-291X(92)91593-F","article-title":"The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin","volume":"189","author":"de Lannoy","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacc.2013.02.058_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","article-title":"Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in\u00a0vitro-in\u00a0vivo correlation using digoxin as a probe drug","volume":"85","author":"Fenner","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2013.02.058_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.CIR.99.4.552","article-title":"Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine","volume":"99","author":"Fromm","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.02.058_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01881526","article-title":"The digoxin-amiodarone interaction","volume":"3","author":"Robinson","year":"1989","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00005344-198704000-00001","article-title":"Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects","volume":"9","author":"Santostasi","year":"1987","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2013.02.058_bib17","first-page":"2189","article-title":"Amiodarone: guidelines for use and monitoring","volume":"68","author":"Siddoway","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jacc.2013.02.058_bib18","article-title":"Dronedarone-induced digoxin toxicity: new drug, new interactions","author":"Vallakati","year":"2011","journal-title":"Am J Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib19","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMoa1109867","article-title":"Dronedarone in high-risk permanent atrial fibrillation","volume":"365","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.02.058_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-198901000-00003","article-title":"Interaction between digoxin and propafenone","volume":"11","author":"Calvo","year":"1989","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jacc.2013.02.058_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1472-8206.2006.00408.x","article-title":"Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein","volume":"20","author":"Bachmakov","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jacc.2013.02.058_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2013.02.058_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.tpj.6500220","article-title":"Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors","volume":"4","author":"Wadelius","year":"2004","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jacc.2013.02.058_bib24","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.2174\/138161210793563338","article-title":"Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management","volume":"16","author":"Douketis","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2013.02.058_bib25","series-title":"Pradaxa (dabigatran etexilate)","year":"2012"},{"key":"10.1016\/j.jacc.2013.02.058_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1742-1241.2009.02286.x","article-title":"Drug and dietary interactions of the new\u00a0and\u00a0emerging oral anticoagulants","volume":"64","author":"Walenga","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacc.2013.02.058_bib27","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2013.02.058_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0091270010393342","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin","volume":"52","author":"Stangier","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2013.02.058_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In\u00a0vitro and in\u00a0vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib30","series-title":"Xarelto (rivaroxaban)","year":"2012"},{"key":"10.1016\/j.jacc.2013.02.058_bib31","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2165\/11596820-000000000-00000","article-title":"Apixaban: first global approval","volume":"71","author":"Watson","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2013.02.058_bib32","series-title":"Eliquis (apixaban)","year":"2013"},{"key":"10.1016\/j.jacc.2013.02.058_bib33","doi-asserted-by":"crossref","first-page":"E1510","DOI":"10.1016\/S0735-1097(11)61510-6","volume":"57","author":"Mendell","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.02.058_bib34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.02.058_bib35","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1476-5381.1996.tb15550.x","article-title":"Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells","volume":"118","author":"Cavet","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacc.2013.02.058_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/phrs.1999.0535","article-title":"P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil","volume":"40","author":"Verschraagen","year":"1999","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacc.2013.02.058_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-5793(93)81540-G","article-title":"P-glycoprotein-mediated transcellular transport of MDR-reversing agents","volume":"324","author":"Saeki","year":"1993","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jacc.2013.02.058_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0928-0987(02)00082-9","article-title":"Effects of 12 Ca2+\u00a0antagonists on multidrug resistance, MDR1-mediated transport\u00a0and MDR1 mRNA expression","volume":"16","author":"Takara","year":"2002","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jacc.2013.02.058_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1349-7006.2003.tb01356.x","article-title":"Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil","volume":"94","author":"Kakumoto","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jacc.2013.02.058_bib40","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2013.02.058_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/00912700022008612","article-title":"Atorvastatin coadministration\u00a0may increase digoxin concentrations by inhibition of intestinal\u00a0P-glycoprotein-mediated secretion","volume":"40","author":"Boyd","year":"2000","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jacc.2013.02.058_bib42","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","article-title":"Impact of P-glycoprotein on clopidogrel absorption","volume":"80","author":"Taubert","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.02.058_bib44","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/clpt.2011.163","article-title":"Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel","volume":"90","author":"Jung","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib45","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.02.058_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ijc.2910560120","article-title":"Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells","volume":"56","author":"Damle","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jacc.2013.02.058_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1067\/mcp.2003.8","article-title":"Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition","volume":"73","author":"Verstuyft","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4062\/biomolther.2010.18.3.343","article-title":"Pharmacokinetic drug interaction between carvedilol and ticlopidine in rats","volume":"18","author":"Choi","year":"2010","journal-title":"Biomol Ther"},{"key":"10.1016\/j.jacc.2013.02.058_bib49","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.110.032250","article-title":"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects","volume":"38","author":"Teng","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacc.2013.02.058_bib50","unstructured":"Marciniak TA. Ticagrelor for acute coronary syndromes, NDA 22-433.\u00a0Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM220192.pdf. Accessed December 13,\u00a02011."},{"key":"10.1016\/j.jacc.2013.02.058_bib51","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and\u00a0Research. Guidance for industry: drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf. Accessed November\u00a02012."},{"key":"10.1016\/j.jacc.2013.02.058_bib52","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/jpet.103.050526","article-title":"Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor","volume":"306","author":"Sahi","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2015.05.026","type":"err","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000}},{"DOI":"10.1016\/j.jacc.2014.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T00:00:00Z","timestamp":1401148800000}}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713012916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713012916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T04:56:30Z","timestamp":1596430590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713012916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":52,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0735109713012916"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.02.058","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}